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httpcense.Abstract Lung cancer is a global problem and its incidence is dramatically increasing and expected
to become the leading cause of cancer deaths. Several molecular genetic abnormalities have been
described in lung cancer, one of the most recent such markers is tumor necrosis factor-related apop-
tosis-inducing ligand (TRAIL).
Objective: To throw an outlook on tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) expression in tissue specimens obtained from lung cancer patients.
Patients and methods: Fifty Patients were included in this work selected on basis of being present-
ing with clinical and/or radiological picture suggestive of lung cancer. They were classiﬁed histop-
athologicallyl into two groups, Group I comprised (37) non small lung cancer patients (NSCLC),
and Group II comprised (13) small lung cancer patients (SCLC). All patients were subjected to
thorough medical history, clinical examination and radiological examination. Fiberoptic broncho-
scopic examination was done with different endoscopic sampling and the obtained specimens were
subjected to special staining procedure for TRAIL expression by immunohistochemistry.
Results: Bronchial biopsy carried the highest diagnostic yield for lung cancer in both groups
(60%) and (24%) in groups I and II, respectively. Histopathologically, the majority of cases01747101.
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482 A.H. Ghoneim et al.(86.48%) of group I were adenocarcinoma, (13.5%) were squamous, while all cases of group II
(100%) were SCLC. TRAIL expression was positive in 67.6% of group I and in 23% of group
II cases. 62.5% of adenocarcinoma patients were TRAIL positive, as well as 40% of squamous cell
carcinoma patients while 23.1% only of SCLC were TRAIL positive. There was no statistical sig-
niﬁcant difference in the degree of cigarette smoking between TRAIL positive and negative subjects.
The sensitivity of TRAIL immunostaining in lung cancer was 67.6%, while its speciﬁcity was 76.9%
with accuracy of 70% in the studied groups.
Conclusion: TRAIL is overexpressed in the majority of NSCLC mainly adenocarcinoma which
indicate that it may become a new adjuvant line for treatment of such cases.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Lung cancer is the leading cause of cancer-related mortality in
the world. NSCLCs represent 75–80% of all types of lung can-
cer, and include squamous cell carcinomas, adenocarcinomas,
and large-cell carcinomas [1].
Non-small cell lung cancer now accounts for about three-
quarters of all cases of lung cancer and most patients continue
to die of progressive metastatic disease despite new therapeutic
strategies and advances in surgical oncology. This failure of con-
ventional therapy is due to metastases as well as resistance to
chemotherapy and radiation. Attempts to overcome resistance
through increased dosage results in unacceptable toxicity [2].
Current interest is focused on the so-called ‘‘death ligands,’’
including TNF, FasL, and TRAIL [3]. Death ligands can trig-
ger apoptosis in tumor cell lines via their cognate cell-surface
death receptors, TNFR1, Fas, and DR4/DR5, respectively
[4,5].
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/Apo-2L) is a typical member of the tumor necrosis
factor family, inducing apoptosis by activating death receptors
[6]. A number of studies have shown that both the membrane-
bound and the soluble extracellular domain of TRAIL can in-
duce apoptosis in a wide variety of tumor cell lines without
affecting most normal cells [7,8].
TRAIL receptor targeting agents represent an anti-cancer
strategy which activity is mainly dependent on the ability to in-
duce apoptosis in tumor cells. Different from other members
of the TNF super family (TNF and FasL), recombinant hu-
man (rh) TRAIL induces apoptosis in various tumor cells
but not in normal cells. Furthermore, it has been demonstrated
that systemic administration of rhTRAIL in mice or non-hu-
man primates results in anti-tumoricidal activity without any
toxic effects on normal tissue [8].
Aim of the work
The aim of this work is to throw an outlook on tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) expression
in tissue specimens obtained from lung cancer patients.
Patients and methods
This study had been carried out at the Chest and Pathology
Departments, Faculty of Medicine, Zagazig University during
the period between October 2008 and July 2011. Fifty patients
were included in this work, (38) males and (12) females. Their
age range was (35–80 years) with a mean (55 ± 10 years).Patients were selected on basis of being presenting with clinical
and/or radiological picture suggestive of lung cancer according
to Spiro [9]. Patients with prior history of malignancies, sever
liver disease, renal and cardiac disease were excluded from the
study; as such critical medical illness may not withstand inva-
sive procedures like bronchoscopy and needle biopsies. Also,
patients with liver disease suffer from bleeding tendency during
the procedures. Patients with unstable angina and life-threat-
ening arrhythmias are not suitable for in invasive techniques.
Lastly the result of TRAIL immunostaining may vary in the
presence of such comorbid conditions. After histopathological
examination, they were classiﬁed into two groups, Group I
comprised (37) NSCLC patients, (28 males) and (9 females)
with mean age (57 ± 11.4 years) and Group II comprised
(13) SCLC patients, (10males) and (3 females) with mean age
(56 ± 9.2 years). All patients were subjected to the following:
(1) Thorough medical history including:
(a) Smoking history.
(b) History of occupational exposure to carcinogenic
elements such as, nickel, asbestos, etc. [10].
(c) Chest and other symptoms suggestive of lung can-
cer [9]. Cough, expectoration, dyspnea, chest pain,
chest wheezes, hemoptysis, dysphagia, hoarseness
of voice, features of Horner’s syndrome, superior
vena cava obstruction symptoms (facial fullness,
swelling of the upper extremities), constitutional
symptoms (fever, chills, anorexia, weakness,
signiﬁcant weight loss), extrathoracic symptoms
due to metastases (headache, nausea, vomiting,
seizures, back pain, abdominal pain, bone pain)
and non metastatic paramalignant manifestations
(ﬂushing, diarrhea, tingling and numbness of
hands or feet).(2) Clinical examination including general and local chest
examination.
(3) Routine laboratory investigations including: com-
plete blood picture, coagulation proﬁle, erythrocyte
sedimentation rate, liver functions tests, blood
urea, serum creatinine and fasting blood sugar
testing.
(4) Radiological examination including:
(a) Plain chest radiography (PA and lateral views)
(b) Computed Chest Tomography (CT). Percutanous trans-
thoracic ﬁne needle aspiration biopsy (TTNA) was done
under CT guidance for 13 patients in this study from
suspected peripheral pulmonary lesions by using spinal
needle gauge 22 for cell block according to Lima [11].
An immunohistochemical study of tumour necrosis 483(c) Assessment of metastatic workup through CT scan of the
upper abdomen, to exclude the liver and adrenals metas-
tasis (done for 8 cases). CT scan of the brain required if
neurological symptoms or signs are present (done for 5
cases). Magnetic resonance image (MRI) is useful when
evaluating a patient with spinal cord compression (done
for 3 cases). Bone scintigraphy was required if patients
report bone pain or if their serum calcium and/or alkaline
phosphatase levels are elevated (done for 15 cases). Stag-
ing of lung cancer is the most accurate means to estimate
prognosis and guide treatment decisions. The characteris-
tics of the primary tumor (T), regional lymph nodes (N),
andmetastatic involvement (M) are used to stageNSCLC
according to the TNM system. Staging of Small-Cell
Lung Cancer was done using the old Veterans Adminis-
tration staging system of ‘‘limited’’ and ‘‘extensive’’’ dis-
ease categories. Limited disease is deﬁned as disease
conﬁned to one hemithorax and the ipsilateral supracla-
vicular nodes. Extensive stage disease is deﬁned as disease
that has spread beyond these conﬁnes. Contralateral hilar
lymph nodes, cervical lymph nodes, or distant organ
metastasis is considered extensive stage disease [11].
(5) Sputum cytology for detection of malignant cells. It was
done for (47) cases, all of them were presenting with pro-
ductive cough.
(6) Fiberoptic bronchoscopic [12] examination using Olym-
pus BF type 10 was one for all cases and well informed
consent were obtained from all patients. Different endo-
scopic sampling was done including: endobronchial
biopsy, bronchial washing, bronchoalveolar lavage
(BAL) and bronchial brushing.
(7) Post bronchoscopic sputum cytology, for detection of
malignant cells [13]. It was done for 50 cases.
(8) Cytological and histopathological examination of all
types of specimens and biopsies and routine parafﬁn
blocks were done from each biopsy sample and two sec-
tions were obtained from each parafﬁn block 4l thick
and were subjected to:Pe
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Group I (NSCLC) Group II (SCLC)(a) Routine hematoxyline and eosin stain to verify
histopathologic type [14]
(b) Special staining procedure (Human TRAIL/TN-
FSF10 Antibody) using monoclonal antibodies
DACO [15] for detection of TRAIL expression:
tumors showing 610% positively stained cells w-
ere considered negative. Samples showing >10%
positively stained tumor cells were considered p-
ositive. All of the stained tumor biopsies were e-
valuated semi quantitatively for intensity of
staining: no staining (0), weakly positive staining
(1), positive staining (2), or strong positive stain-
ing (3).0
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Clinical  presentation
Figure 1 Distribution of presenting symptoms among both
groups.Statistical analysis
Data were analyzed using statistical package for social science
(SPSS) version (Chicago, IL, USA) [16].
Results
This table shows that there was no statistical signiﬁcant differ-
ence in the mean age of the 2 studied groups. There was malepredominance in the studied groups, where males represent
75.7% and 76.9% in groups I and II, respectively, with no sig-
niﬁcant statistical difference. 10.8% of group I patients were
exposed to the risk of carcinogens in their work place while
no such risk was present in group II patients with no statistical
signiﬁcant. 86.5% of group I patients were smokers (10.8% of
them were Ex and the other 75.68% were current smokers) and
76.9% of group II patients were smokers (23% were Ex and
the other 53.84% were current smokers).Smoking distribution
between the 2 groups was statistically signiﬁcant (P< 0.05).
Fig. 1 shows that the major presenting symptoms of lung
cancer were cough (78.4% in group I and 100% in group II pa-
tients), dyspnea (75.7% in group I and 100% in group II pa-
tients) and expectoration (70.3% in group I and92% in
group II patients), while hoarseness of voice (16.2% in group
I and 30.8% in group II patients) and dysphagia (5.4% in
group I only) were the least presenting symptoms.
Fig. 2 shows that the presence of hilar shadow (54.1% in
group I and 62% in group II) and mass lesion (43.2% in group
I and 38% in group II) were the predominant radiological pic-
tures in both groups.
Fig. 3 shows that pulmonary involvement of lung cancer in
CT scanning were present in (67.6 of group I and 69.2% of
group II), mass lesions were present in (70.3% in group I
and 92.% of group II), and both hilar and medistinal lymph
nodes involvement were found in (51.4% of group I and
61.5% of group II).
Fig. 4 shows that the major bronchoscopic ﬁndings in both
groups were broad spur (54%,61.5% in group I and group II,
respectively) and Mass lesion (48.6%,61.5% in group I and
group II, respectively), followed by bronchial narrowing
(40.5%,46% in group I and group II, respectively).
Table 2 shows that bronchial biopsy carried the highest
diagnostic yield for lung cancer (60% and 24% in groups I
and II, respectively), followed by bronchoalveolar lavage
Figure 2 Distribution of the different radiological presentation
among both groups.
Figure 3 Distribution of the CT scanning data among both
groups.
Figure 4 Analysis of the different bronchoscopic ﬁndings among
the groups.
Photo 1 Strongly positive reaction (+++) of the malignant
acini adenocarcinoma grade II (immunostaining for TRAIL
400·).
Photo 2 Negative reaction (0) of the acini of adenocarcinoma
type grade II (immunostaining for TRAIL 400·).
484 A.H. Ghoneim et al.(50% and16% in groups I and II, respectively) and post bron-
choscopic sputum (34% in group I and 16% in group II).
This table shows that all cases (37 cases) of group I were of
non small cell lung cancer type (32 cases were of adenocarci-
noma type, 5 were of squamous cell type) while all cases (13)
of group II were of small cell cancer.
Table 4 shows that TRAIL expression was positive in
67.6% of group I cases and 23% of group II cases. This differ-
ence in TRAIL expression among the 2 groups was statistically
highly signiﬁcant (P< 0.01).
Table 5 shows that (62.5%) of adenocarcinoma cases were
TRAIL positive, while 40% of squamous and 23.07% of small
cell cases were TRAIL positive. There was a high signiﬁcant
statistical difference in TRAIL immunostaining among differ-
ent histopathological types of lung cancer (P< 0.001).
Table 6 shows that there was no statistical signiﬁcant differ-
ence between male and female distribution as regard TRAIL
immunostaining in both groups.
Table 7 shows that, there was no statistical signiﬁcant dif-
ference in the degree of cigarette smoking between TRAIL po-
sitive and negative subjects (P> 0.05).
Table 8 shows that the sensitivity of TRAIL in lung cancer
was 67.6%, while its speciﬁcity was76.9% with accuracy of
70%. (Photos 1 and 2).
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Lung cancer is the most common cause of cancer mortality
worldwide for both men and women, causing approximately
1.2 million deaths per year. In the United States, annually
there are 200,000 new cases of lung cancer and 160,000 deaths,
and recently, it surpassed heart disease as the leading cause of
smoking-related mortality [17].
The incidence of lung cancer in Egypt is dramatically
increasing and expected to become the leading cause of cancer
deaths [18].
Cancer is a global problem, it comes next to cardiovascular
disease as the cause of mortality in Egypt, lung cancer consti-
tutes 2.8% of total malignancy in national registry published
by NCI 2007 [19].
Unfortunately, in spite of the marked progress in the treat-
ment of the disease many patients diagnosed with lung cancer
still die because of their disease, but recent progress in the
molecular biology with the increased understanding of molec-
ular abnormalities in lung cancer, recent research efforts have
focused heavily on identifying molecular targets and using this
knowledge to develop molecular-targeted therapies [7]. The
mean age at time of diagnosis was 57.08 ± 11.4 and
56.15 ± 9.2 in groups I and group II, respectively. 96.8%
and 100% of cases in groups I and group II, respectively, were
(40) years or above (Table 1). This ﬁnding is concomitant with
that recorded by Ashour [20], (96%); Hasan [21], (96%);
Mohamed et al. [22], (96%); El-Gamal et al. [23], El-Hefni
et al. [19]. The present work elucidated that there was male
predominance in the studied groups, where males represent
75.7% and 76.9% in groups I and II, respectively, with male
to femal ratio (3:1) and this ratio is typical with that recorded
by El-Aassar [24], and El-Hefni et al. [19]. As per 2007 statis-
tics, NCI registry, lung cancer was the fourth most frequently
diagnosed cancer among males in Egypt, accounting for 1.54%
of all cases. In females, lung cancer ranked the 9th, accounting
for 2.8% of all cancer cases in females diagnosed in that year
and the difference in the previous ratio may be attributed to
the different number and locality of the studied cases andTable 1 Demographic characteristics of the studied patients.
Character Group I
(NSCLC)
No = 37
Group II
(SCLC)
No = 13
X2 P
No % No %
Age (in years)
Range 35–80 43–72 t
Mean 57.08 ± 11.4 56.15 ± 9.2 0.264 0.79
Sex
Female 9 24.3 3 23 0.008 0.92
Male 28 75.7 10 76.9
Occupation history 4 10.8 0 0 1.53 0.21
Smoking history
*Cig smoking
Non smoker 5 13.5 3 23.7 Fisher 0.35
Current 28 75.68 7 53.84 6.08 0.07
Exsmoker 4 10.8 3 23.7 Fisher 0.41
*Goza smoking 24 64.9 7 532 0.49 0.481the high male to female ratio can explained by the fact that
males more exposed to smoking, air pollution and occupa-
tional factors. It is now believed that males and females may
differ in their susceptibility to carcinogenic effects of tobacco
smoke and this difference may be due to differences in DNA
repair mechanisms, although still considered controversial, in
addition, differences in response to certain biologic therapies
(e.g., epidermal growth factor inhibitors) and antiangiogenic
agents have been observed between sexes [25].
In the current series, 10.8% of group I were exposed to an
occupational risk in their work placewhile no such riskwas pres-
ent in Group II and this result was statistically non signiﬁcant.
This result questioned the minimal role of such factors in carci-
nogenesis and it runs parallel with the literature data in this con-
cern where Wynder et al. [26], stated that beside tobacco
smoking, a number of industrial process and byproducts my in-
crease the risk of lung cancer including arsenic, bischloromethyl
ether, chromium, nickel, polycyclicaromatic hydrocarbons,
chloromethyl and methyl ether. Molina et al. [27] stated that
Asbestos exposure has been shown to be strongly associated
with the causation of lung cancer, malignant pleural mesotheli-
oma, and pulmonary ﬁbrosis. It increases the risk of developing
lung cancer by as much as 5 times. Tobacco smoke and asbestos
exposure act synergistically, and the risk of developing lung can-
cer for persons who currently smoke tobacco and have a history
of asbestos exposure approaches 80–90 times that of control
populations. The role of smoking as the most important cause
of lung cancer is undeniable [28]. In this study, it was found that
86.5% of group I patients were smokers (10.8% of themwere ex
smoker and the other 75.68%were current smokers) and 76.9%
of group II patients were smokers (23% were Ex and the other
53.84%were current smokers) (Table 1). This result is consistent
with that of Ashour [20]; Capwell et al. [29]; El-Shahat et al. [30];
Mobasher et al. [31]; Fawzy et al. [32]; El-Gamal et al. [23]; Doll
et al. [26]; Alberg et al. [33] and El-Hefni et al. [19] who stated
that three quarters of lung cancer cases can be attributed to
smoking and the primary risk factor for the development of lung
cancer is cigarette smoking, which is estimated to account for
approximately 90% of all lung cancers. The major clinical pre-
sentations of lung cancer in this work were cough (78.4% in
group I and 100% in group II patients), dyspnea (75.7% in
group I and 100% in group II patients) followed by expectora-
tion (70.3% in group I and 92% in group II patients), chest pain
(51.4% in group I and 69.2% in group II patients), chestwheezes
(45.9% in group I and 53.8% in group II patients), while, hem-
optysis (18.9% in group I and 38% in group II patients), horse-
ness of voice (16.2% in group I and 30.8% in group II patients),
and dysphagia (5.4% in group I patients only) were the least pre-
senting symptoms in both groups (Fig. 1). This result is consis-
tent with El-Gamal et al. [23] who reported that cough was the
major clinical manifestation of lung cancer (100%), followed
by dyspnea (86%), expectoration (48%)while horseness of voice
(20%), dysphagia (4%)were the least presenting symptoms. In a
study byMohamed et al. [22], coughwas themajor clinical man-
ifestation of lung cancer (98%), followed by expectoration
(96%), dyspnea (86%), hemoptysis (48%), chest pain (42%),
while chest wheezes (26%) horseness of voice (14%), dysphagia
(10%) were the least presenting symptoms.
Fergusson [34], stated that cough is by far the most com-
mon symptom of lung cancer at presentation and any new
cough that persists longer than 2 weeks should be regarded
with suspecicion, especially in patients over the age of 40 years
Table 3 Distribution of the studied groups in relation to their
histopathological diagnosis.
Groups Group I
(NSCLC) No= 37
Group II
(SCLC) No = 13
No % No %
Histopathology
Adenocarcinoma 32 86.48 0 0.0
Squamous cell 5 13.5 0 0.0
Small cell carcinoma 0 0.0 13 100
Total 37 100 13 100
486 A.H. Ghoneim et al.who are tobacco smokers. Similar reports were recorded by
Margolis [35] who stated that cough was the common initial
symptom of lung cancer noted in (75%) case, followed by
dyspnea in (60%) of cases, chest pain (45%) of cases, hemopt-
ysis alone in (10%) and in combination with other symptoms
in up to (50%) of cases while hoarseness of voice (18%), chest
wheeze (10%), dysphagia (2%) were the least presenting symp-
toms. Spiro et al. [9] who stated that cough is reported to be
the most common presenting symptoms of lung cancer
(75%). followed by dyspnea in (58%) of cases, hemoptysis in
(57%),chest pain in (49%) of cases, while hoarseness of voice
(18%),chest wheeze and dysphagia (2%) were the least pre-
senting symptoms. Regarding the radiological presentation
of lung cancer in this study, the commonest radiological ﬁnd-
ings were mass lesion (43.2% in group and 61.9% in group II)
and hilar shadow (54.1% in group I 38.5% group II), followed
by heterogenous opacity (43.3% in group I and 30.7% group
II), broad superior mediastinum (29.7% in group I and
15.4% in group II), while pleural effusion (24.3% in group I
and 23.7% in group II), elevated hemidiaphragm (18.9%) in
group I and15.3% in group II), complete opaciﬁcation of hem-
ithorax (16.2% in group I and7.6% group II), bilateral multi-
ple nodules (13.5% in group I only), and cavitary lesion (5.4%
in group I only) were the least presenting features (Fig. 2). This
result is in agreement with Mohamed et al. [22] who Found
that both hilar shadow (54%) and mass lesion (54%), were
the commonest presenting features, followed by heterogeneous
opacity (30%), broad superior mediastinum (30%), pleural
effusion (24%), complete opaciﬁcation of hemithorax (18%),
bilateral multiple nodules (10%) and cavitary lesion (4%). Dif-
ferent records were reported by Fawzy et al. [32] who found
that mass lesion was the commonest radiological ﬁnding
(34%), followed by hilar shadow (27.2%), heterogenous opac-
ity (18.1%), pleural effusion (10.9%), elevated hemidiaphragm
(10.9%), complete opaciﬁcation of hemithorax (3.6%), broad
superior mediastinum (1.8%). Seaton et al. [10] reported that
the chest radiograph is nearly always abnormal in patients
with lung cancer at presentation and prominence of a hilar
shadows is a common early ﬁnding in the case of a central tu-
mor while mass shadow is in the case of a more peripheral sit-
uated tumor. Regarding the bronnchoscopic ﬁnding, this study
showed the major bronchoscopic ﬁndings in both groups were
broad spur (54%, 61.5% in group I and group II, respectively)
and Mass lesion (48.6%, 61.5% in group I and group II,
respectively), followed by bronchial narrowing (40.5%, 46%
in group I and group II, respectively) while carinal broadeningTable 2 Yield of different diagnostic techniques in the diagnosis o
Group Group I (NSCLC) No = 37
Technique result Positive Negative
No % No %
Diagnostic technique
Pre Bronchoscope sputum No = 47 6 12.8 23 48.9
Post Bronchoscope sputum No = 50 17 34 19 38
Bronchial biopsy No = 50 30 60 7 14
Broncho alveolar lavage No = 50 25 50 12 24
Bronchial aspirate No = 50 14 28 23 46
Brush biopsy No = 48 12 25 23 47.9
CT guided biopsy No = 13 3 23 7 53.8(18.9% of group I and 38.5% of group II), vocal cord paralysis
(18.9% of group I and 30.7% of group II), bronchial obstruc-
tion (8% group I and 30.7% of group II), and tracheal involve-
ment (13.5% group I, 7.6% of group II), were the least
presenting features (Fig. 3). Mohamed et al. [22] found that
bronchial involvement was detected in (84%) of cases followed
by carinal broadening in (83%), vocal cord paralysis in (14%)
and tracheal involvement in (4%) of cases. On review of the
diagnostic techniques utilized in this study, it was clear that
bronchial biopsy carried the higher diagnostic yield (60%
and 24% in groups I and II, respectively) for the diagnosis
of lung cancer (Table 2) and this result is consistent with Han-
son and Collins [36] (45%); El-Shahat et al. [30] (56%) and
Mobasher et al. [31]; (53%). also, higher results were recorded
by Zavala [37] (85%); Shure and Astarita [38] (88%); Mousta-
fa et al. [39] (85%); Fawzy et al. [31] (90%); Mohamed et al.
[22] (84%) and El-Gamal et al. [23] (82%). This difference
can be attributed to the variation in number and adequacy
of tissue biopsy specimens obtained in one hand, and the dif-
ferent locations of the tumor lesions on the other hand. Hist-
opathologically, all cases (37 cases) of group I were of non
small cell lung cancer type (32 cases were of adenocarcinoma
type, 5 were of squamous cell type) while all cases (13) of group
II were of small cell cancer (Table 3).In a study by El-Shahat
et al. [30], it was founded that, (20%) were squmous cell carci-
noma, (24%) adenocarcinoma, (20%) small cell carcinoma,
(16%%) large cell carcinoma, (8%) metastatic carcinoma
and (12%) were unclassiﬁed carcinoma. In a study by Hasan
[21], it was found that (42.4%) squmous cell carcinoma,
(24%) adenocarcinoma, (20%) small cell carcinoma, (16%)
large cell carcinoma and (3%) were carcinoid tumour.
Mobasher et al. [31]; recorded that (32.1%) small cellf lung cancer.
Group II (SCLC) No = 13
Suspicious Positive Negative Suspicious
No % No % No % No %
6 12.8 1 2 10 22.3 1 2
1 2 8 16 5 10 0 0.0
0 0.0 12 24 1 2 0 0.0
0 0.0 8 16 5 10 0 0.0
0 0.0 6 12 7 14 0 0.0
0 0.0 7 14.5 6 12.5 0 0.0
0 0.0 0 0.0 3 23 0 0.0
An immunohistochemical study of tumour necrosis 487carcinoma, (3.8%) large cell carcinoma, (6.4%) adenocarci-
noma, (19.2%) squmous cell carcinoma and (38.5%) were
undifferentiated cell carcinoma. Fawzy et al. [32] found that
(74%) of lung cancer patients were adenocarcinoma, (18%)
were squmous cell carcinoma and (8%) were small cell carci-
noma. Korraa et al. [40] reported that (44%) small cell carci-
noma, (20%) squmous cell carcinoma, (20%) large cell
carcinoma and (16%) adenocarcinoma.
Mohamed et al. [22] reported that (82%) were adenocarci-
noma, (4%) bronchoalveolar carcinoma, (4%) squmous cell
carcinoma, (4%) lymphoma and (2%) anaplastic carcinoma.
It is well known that patterns of histological types of lung can-
cer have changed over time. In the United States of America
and many other countries, adenocarcinoma has become the
most commonly diagnosed type of lung cancer [41]. In Europe,
despite squamous cell carcinoma remaining the most predom-
inant cell type, the rates of adenocarcinoma have increased
steadily over time [42–44]. Further analysis of histological
types by nationality revealed that adenocarcinoma predomi-
nated in Egyptian population and this contradictory may be
attributed to some hypotheses, such as the changes in the char-
acteristics of cigarettes and the consequent changes in the
doses of carcinogens inhaled, the advances in diagnostic tech-
niques for lung cancer and the possible role of occupational
exposure and pollution, have been postulated to explain the re-
cent shift in histopathology [45–46]. Nevertheless, the predom-
inance of adenocarcinoma among lung cancer types in Egypt
and squamous cell carcinoma in other Arab counties like Gulf
area is a matter of interest that may be addressed in future
studies.
Tumor necrosis factor-related apoptosis-inducing ligand or
Apo 2 ligand (TRAIL/Apo2L) is a member of the tumor necro-
sis factor (TNF) family of ligands capable of initiating apoptosis
through engagement of its death receptors. TRAIL induces
apoptosis through interacting with its receptors. So far, four
homologous human receptors for TRAIL have been identiﬁed,
including DR4, KILLER/DR5, TRID/DcR1/TRAIL-R3 and
TRAIL-R4/DcR2, as well as a ﬁfth soluble receptor called
osteoprotegerin (OPG), which was identiﬁed initially as a recep-
tor for RANKL/OPGL and was shown later to bind TRAIL.
Both the death receptors DR4 and DR5 contain a conserved
death domain (DD) motif and signal apoptosis. The other three
receptors appear to act as ‘decoys’ for their ability to inhibit
TRAIL-induced apoptosis when overexpressed. Decoy receptor
1 (DcR1) andDcR2have close homology to the extracellular do-
mains of DR4 and DR5. DcR2 has a truncated, nonfunctional
cytoplasmic DD, while DcR1 lacks a cytosolic region and is an-
chored to the plasma membrane through aglycophospholipid
moiety. The physiological relevance of OPG as a receptor for
TRAIL is unclear, however, because the afﬁnity for this ligand
at physiological temperatures is very low [8].
Two main signaling pathways have been delineated to initi-
ate the apoptotic suicide program in mammalian cells, the
intrinsic and extrinsic pathways. The cell extrinsic pathway is
initiated by members of the TNF superfamily. TRAIL has
been shown to induce apoptosis through binding its respective
receptors, DR4 and DR5. Ligation of TRAIL to its receptor
results in trimerization of the receptor and clustering of the
receptor’s intracellular DD, leading to the formation of the
death-inducing signaling complex (DISC). Trimerization of
the DDs leads to the recruitment of an adaptor molecule,
FADD, and subsequent binding and activation of caspase-8and -10. Activated caspase-8 and -10 then cleave caspase-3,
which in turn leads to cleavage of the death substrates. The cell
intrinsic pathway triggers apoptosis in response to DNA dam-
age, cell cycle checkpoint defects, mitotic catastroph hypoxia,
loss of survival factors or other types of severe cell stresses.
The pathway involves the activation of the proapoptotic arm
of the Bcl-2 gene superfamily, which in turn engages the mito-
chondria to cause the release of apoptogenic factors such as
cytochrome c and SMAC/DIABLO into the cytosol. In the
cytosol, cytochrome c binds the adaptor APAF-1, forming
an ‘apoptosome’ that activates the apoptosis-initiating prote-
ase caspase-9. In turn, caspase-9 activates ‘executioner’ prote-
ase caspase-3, -6, and -7. SMAC/DIABLO promotes apoptosis
by binding to inhibitor of apoptosis (IAP) proteins and pre-
venting these factors from attenuating caspase activation.
The intrinsic and extrinsic apoptosis signaling pathways com-
municate with each other. Caspase-8 has been shown to cleave
the proapoptotic Bcl-2 family member Bid. The cleavage of
Bid by caspase-8 and the translocation of truncated Bid to
the mitochondria to promote cytochrome c release through
interaction with Bax and Bak provide a plausible mechanistic
link between the extrinsic and intrinsic pathways. This appar-
ently ampliﬁes the apoptotic signal following death receptor
activation, and different cell types may be more reliant on this
ampliﬁcation pathway than others. kidney, central nervous
system, and thyroid. Mice bearing solid tumors, when injected
with soluble TRAIL, showed increased tumor cell apoptosis,
suppressed tumor progression, and improved survival without
any normal-tissue toxicity. Administration of TRAIL to mice
transplanted with human tumor xenografts derived from colon
carcinoma, breast cancer, mammary adenocarcinoma, multi-
ple myeloma, or malignant glioma, exerted marked antitumor
activity without systemic toxicity. As an alternate to adminis-
tration of soluble TRAIL, adenoviral gene therapy vehicles for
TRAIL have been utilized with promising results both in vitro
and in small experimental animals. Prolonged survival of nude
mice bearing ovarian cancer xenografts have been reported
upon administration of adenoviral vectors harboring the
TRAIL gene. Therapeutic efﬁcacy of TRAIL gene therapy
has also been demonstrated with colon cancer, prostrate tu-
mors, glioblastoma, breast cancer, and hepatocellular carci-
noma. Taken together, these results indicate substantial
promise for TRAIL in the treatment of human cancers [6].
The result of the present study showed that (67.6%) of
groups I and (23%) of group II were positive for TRAIL
and this difference in TRAIL expression among the 2 groups
was statistically highly signiﬁcant (Table 4). Similar reports
were recorded by Jin et al. [47]. Different ﬁgures were recorded
by other investigators. Wiezorek et al. [48] showed that the
death receptors for TRAIL in NSCLCs was expressed in
82% and absence of this receptors in SCLC. Voortman et al.
[7] showed that All the NSCLC cell lines are positive for
TRAIL receptor, lack of TRAIL-R2 expression was found in
eight of 20 (40%) SCLC cell lines and in eleven of 20 (55%)
NSCLC cell lines. Interestingly, in primary NSCLC, TRAIL-
R2 was over expressed in seven (23%) of the 30 tumors tested,
and all primary tumors expressed TRAIL-R2. Spierings et al.
[15] showed that TRAIL receptors were expressed in 82% of
NSCLC this expression may be translated into a successful
rhTRAIL therapy.
Hopkins-Donaldson et al. [49] have demonstrated the resis-
tance of small cell lung cancer cell lines to TRAIL-induced
Table 4 Distribution of the studied groups in relation to the
result of TRAIL immunostaining.
Group Group I
(NSCLC) N= 37
Group II
(SCLC) N= 13
X2 P
No % No %
TRAIL immunostaining
Positive 25 67.6 3 23 7.73 0.005
Negative 12 32.4 10 76.9
488 A.H. Ghoneim et al.apoptosis, which could be explained by an absence of TRAIL-
R1 mRNA expression and a deﬁciency of surface TRAIL-R2
protein. Reduced levels of TRAIL-R1 in SCLC tumors com-
pared to NSCLC tumors justify the resistance of SCLC cells
to apoptosis mediated by death receptors. In the present study,
it was found that (62.5%) of adenocarcinoma cases were
TRAIL positive, while 40% of squamous and 23.07% of small
cell cases were TRAIL positive and this result was statistically
signiﬁcant (Table 5). This result is consistent with that re-
ported by Tsuchiya et al. [50] who reported that reported that
TRAIL is over expressed in 75% of adenocarcinoma, 30% of
squamous and 15% of small cell, Srivastava [51] reported that
TRAIL is over expressed in 90% of adenocarcinoma, 40% of
squmaous cell and lack of TRAIL expression in small cell line.
This difference in TRAIL expression between adenocarcinoma
and squamous cell is explained by Tsuchiya et al. [50] who re-
ported a more frequent loss of chromosomes 3p and 17p in
squamous cell carcinoma compared with adenocarcinoma.
These differences between the two histopathological types
might be caused by exposure to different carcinogenic agents
and inactivation of chromosome 13q might not be as impor-
tant in the genesis of adenocarcinoma, since allelic loss was rel-
atively infrequent (19%). Loss of heterozity (LOH) on
chromosome 2q was observed only in adenocarcinoma andTable 5 The relationship between TRAIL immunos
in the studied cases (Total = 50).
Histopathological examination Squamous cells
(No = 5)
A
(
No % N
TRAIL
immunostaining
Positive 2 40 2
Negative 3 60 1
Table 6 Sex distribution of groups as regard TRAI
Sex Group I (NSCLC) No = 37
Male no = 28 Female no = 9
No % No %
TRAIL immunostaining
Positive 21 75 4 44
Negative 7 25 5 55.5
P 0.11implicates the possible existence of a tumor suppressor gene
on this chromosomal arm associated with adenocarcinoma
but not with squamous cell carcinoma [52].
The proapoptotic Bcl-2 family member Bax is a frequent tar-
get formutation in a subset ofmismatchrepair (MMR)-deﬁcient
human tumors. It has been found that Bax is required for
TRAIL-induced apoptosis of certain cancer cell lines, possibly
by allowing the release of second mitochondria-derived activa-
tor of caspases (Smac)/direct IAP-binding family protein with
low pH (DIABLO) and antagonizing the IAP protein family.
Reintroduction of Bax into Bax-deﬁcient cells restored TRAIL
sensitivity. It was found that the tumor suppressor p53 was re-
quired for sensitizing theBax-deﬁcient tumors toTRAILby che-
motherapy, and the p53 downstream transcriptional target gene
DR5 contributes signiﬁcantly to TRAIL sensitization. Apopto-
sis induction in response to most DNA-damaging drugs usually
requires the function of the tumor suppressor p53, which en-
gages primarily the intrinsic apoptotic-signaling pathway.
TRAIL induces apoptosis in a variety of cancer cell lines regard-
less of p53 status, and therefore it might be a useful therapeutic
strategy, particularly in cells in which the p53-response pathway
has been inactivated, thus helping to circumvent resistance to
chemo- and radiotherapy. Although one of the attractive fea-
tures of TRAIL is its ability to kill cancers with mutations in
the p53 gene, the combination ofTRAILwith chemotherapeutic
agents has been found to be particularly effective in killing can-
cers with wild-type p53, presumably through induction of DR5
expression. Downstream of the TRAIL DISC, tumour resis-
tance can be mediated by overexpression or mutations of Bcl-2
or IAP (inhibitor of apoptosis proteins) family members [49].
While the main function of TRAIL is the induction of cell
death, accumulating evidences also suggest that this ligand is
able to signal non-apoptotic pathways, such as Akt, NF-jB
and MAPK, involved in cell survival and proliferation. Akt ki-
nase was proposed to play a protective role against TRAIL tox-
icity in many tumour cells. Yet some Akt inhibitors such astaining and histopathological types of lung cancer
denocarcinoma
No = 32)
Small cell
(No = 13)
X2 P
o % No %
0 62.5 3 23.07 17.69 0.001
2 37.5 10 76.9
L immunostaining result.
Group II (SCLC) No = 13
Male no = 10 Female no = 3
No % No %
2 20 1 33
8 80 2 66.6
1.0
Table 7 The relation between the degree of cigarette smoking and TRAIL immunostaining result in the studied groups.
Pack/year Group I (NSCLC) No = 37 Group II (SCLC) No = 13
Mild No = 5 Moderate No = 11 Heavy No = 8 Mild No = 1 Moderate No = 4 Heavy No = 5
No % No % No % No % No % No %
TRAIL immunostaining
Positive 3 60 10 90.9 4 50 0 0.0 1 25 1 20
Negative 2 40 1 9 4 50 1 100 3 75 4 80
X2 4.11 0.31
P 0.13 0.85
Table 8 Validity of TRAIL immunostaining
Group Group I (NSCLC) N=37 Group II (SCLC) N=13 X2 P
No % No %
TRAIL immunostaining
Positive 25 67.6 3 23 7.73 0.05
Negative 12 32.4 10 76.9
Sensitivity = 67.6 (50.2–81.4). Speciﬁcity = 76.9 (46.0–93.8). Predictive value: Positive = 89.3 (70.6–97.3). Nega-
tive = 45.0 (25.1–67.3). Accuracy 35/50 = 70%.
An immunohistochemical study of tumour necrosis 489amiloride, complestatin, quercetin, sulforaphane, arsenic or
EGFR inhibitor enhance TRAIL-mediated apoptosis. On the
other hand however, more speciﬁc inhibitors of Akt (e.g.,
LY294002, Wortmannin, PI3K siRNA) were shown to be po-
tent TRAIL inhibitors. TRAIL is thought to induceNF-jBacti-
vation through the serine/threonine kinase RIP1. Likewise, the
NF-kBpathway is thought to inhibit TRAIL-induced cell death,
but the issue remains controversial. NF-jB activation has either
been shown to inhibit, or to promoteTRAIL-induced apoptosis.
Among theMAPK superfamily, p38, ERK and JNK, would fa-
vour TRAIL-induced apoptosis, whereas ERK would display
either anti-apoptotic or pro-apoptotic functions. These appar-
ent controversies could be due to our poor understanding of
the TRAIL signalling pathway, and the molecular mechanisms
involved in its regulation could be more complex than antici-
pated [51].
The present series elucidated that 75% and 20% of males in
groups I and group II, respectively, and 44.4% and 33% of fe-
males in groups I and group II, respectively, were positive for
TRAIL expression (Table 6). This result was of no statistical
signiﬁcant difference.
This ﬁnding is in agreement with Shi et al. [53] Thorburn
[54]; McGrath [55] and Kris et al. [52] who stated that no sig-
niﬁcant relationship between TRAIL status and patient sex. In
this study, there was no statistical signiﬁcant difference in the
degree of cigarette smoking between TRAIL positive and neg-
ative subjects in both groups (Table 7). This result is in agree-
ment with results shown by Srivastava [51]; Zhang et al. [56]
and Shi et al. [53] who found that no signiﬁcant relationship
between the degree of cigarette smoking and TRAIL status.
This is in disagreement with Kwon et al. [57]; Perez et al.
[58] and Morissette et al. [59], who reported that there was a
signiﬁcant correlation between TRAIL apoptosis and the
amount of life time cigarette consumption.
This ﬁnding goes parallel with the fact that H2O2 and ciga-
rette smoke sensitized cells to TRAIL-mediated apoptosis
in vitro. In fact, the cellular response to injury seems to beextremely important in allowing the TRAIL signaling pathway
to induce apoptosis in various cell types. Thus, cellular re-
sponse of the lung to injury induced by oxidative stress can
lead to an increased alveolar sensitivity to TRAIL-mediated
apoptosis [52]. This difference may be explained by the varia-
tions in the ability to metabolize tobacco carcinogens between
different population. The Present work showed that the sensi-
tivity of TRAIL in lung cancer was 67.6%, while its speciﬁcity
was 76.9% with accuracy of 70% in the studied groups (Ta-
ble 8), these observations are consistent with that reported
by McGrath [55] who reported the speciﬁcity of TRAIL immu-
nostaining in lung cancer was 80% while its speciﬁcity was
78% with accuracy of 80%.
False negative results of immunohistochemestry are due to
technical (e.g., ﬁxation) artefacts, beside that In the present
study, TRAIL expression was determined immunohistochemi-
cally in parafﬁn-embedded sections where receptors were
detectable, but no membranous staining pattern was observed.
However, this does not preclude the presence of DR4 or DR5
on the cell surface, because immunohistochemistry is not an
optimal technique to detect membranous staining. Moreover,
Zhang et al. [56] demonstrated that, although present on the
cell surface, both DR4 and DR5 are predominantly located
in the trans-Golgi network. Furthermore, they suggested that
the localization in the trans-Golgi network might be a common
feature of apoptosis-inducing TNF family receptors, because
Fas and TNF were also reported to be located in the trans-
Golgi network.
Conclusion
(1) Apoptosis is frequently dysregulated in human cancers,
and recent advancements in our understanding of the
regulation of programmed cell death pathways has led
to the development of novel agents to reactivate apopto-
sis in malignant cells. The activation of cell surface death
490 A.H. Ghoneim et al.receptors by tumor necrosis factor–related apoptosis-
inducing ligand (Apo2L/TRAIL) and death receptor
agonists represent an attractive therapeutic strategy to
promote apoptosis of tumor cells.
(2) TRAIL is overexpressed in the majority of NSCLC
mainly adenocarcinoma. This indicate that rh TRAIL
therapy may become a new adjuvant line for treatment
of such cases.
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